Rat fibroblasts were infected with a retroviral vector containing the cDNA for rat tyrosine hydroxylase [TH; tyrosine 3-monooxygenase; L-tyrosine, tetrahydropteridine:oxygen oxidoreductase (3-hydroxylating), EC 1.14.16.2]. A THpositive clone was identified by biochemical assay and immunohistochemical staining. When supplemented in vitro with pterin cofactors required for TH activity, these cells produced L-dopa and released it into the cell culture medium. Uninfected control cells and fibroblasts infected with the TH vector were grafted separately to the caudate of rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. Only grafts containing TH-expressing fibroblasts were found to reduce rotational asymmetry. These results have general implications for the application of gene therapy to human neurological disease and specific implications for Parkinson disease.
A strategy for gene therapy, in which appropriate target cells are removed from the body, genetically modified in culture, and then implanted back into the body, has attracted considerable attention (1, 2) . Recently, this strategy has been applied to the central nervous system by implanting genetically modified fibroblasts into the brain (3) (4) (5) . The present study was undertaken to determine whether this approach could be used to reduce behavioral abnormalities in an animal model of human neurological disease.
Parkinson disease may be an ideal candidate for treatment with this approach since the neurological abnormalities are known to result from degeneration of a specific class of cells, the dopaminergic neurons of the nigrostriatal pathway. The clinical signs of the disease can be ameliorated by replacement of L-dopa, the precursor of dopamine. Fibroblasts genetically modified to produce L-dopa might be capable of altering the phenotype of this disease after implantation into the brain. To investigate this possibility, a rat fibroblast cell line was infected in vitro with a retroviral vector containing the rat cDNA for the enzyme tyrosine hydroxylase [TH; tyrosine 3-monooxygenase; L-tyrosine, tetrahydrobiopteridine:oxygen oxidoreductase (3-hydroxylating), EC 1.14.16.2] . This enzyme, in the presence of the cofactor tetrahydropterin, catalyzes the conversion of tyrosine to L-dopa. Since tyrosine and tetrahydropterin are readily available to cells of the brain (6) , TH-expressing fibroblasts should be capable of producing L-dopa when implanted intracerebrally. In this report, we demonstrate that genetically modified fibroblasts can produce and release L-dopa in vitro, and they can reduce behavioral abnormalities in an animal model of Parkinson disease.
METHODS
A retroviral vector containing the full-length rat TH cDNA (LThRNL) was derived from the Moloney murine leukemia virus (Fig. 1 ). This vector expresses TH from the 5' long terminal repeat (LTR) and the selectable bacterial neomycinresistance gene (neo) from an internal Rous sarcoma virus (RSV) promoter (7) . A 1688 base-pair (bp) BamHI/Sph I fragment from the plasmid pTH-54 (8) (9) containing the rat TH cDNA, a 1321-bp HindIII/Sma I fragment of neo from the plasmid pSV2neo (10), a 300-bp BamHI/HindIII fragment from the plasmid pUCRH containing a modified RSV promoter (J.-K. Yee, personal communication), and LTR sequences derived from the LPL2 vector (11) were ligated and cloned by standard methods (12) . The polyadenylylation signal within the RSV promoter was changed from AATAAA to AGCAAA by site-directed mutagenesis to allow full-length transcripts from the 5' LTR promoter to the polyadenylylation site within the 3' LTR.
Plasmid DNA containing the LThRNL provirus was transfected by the calcium phosphate method (13) into the amphotropic helper line PA317 (14) , and cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (DMEM/FCS). Two days posttransfection, medium from these cells was filtered and used to infect the ecotropic helper line qi-2 (15) . Producer cells were selected for expression of neo by growth in medium containing 400 ,ug of the neomycin analog G418 per ml. The G418-resistant qi-2 clone that contained the highest level of TH activity and produced the highest titer of virus (5 x 105 per ml) was used for subsequent production of virus.
Immortalized rat fibroblasts of the 208F cell line (16) For immunohistochemical labeling of these cells in vitro, uninfected fibroblasts or 208F/TH8 fibroblasts were grown on microscope slides, fixed with 4% paraformaldehyde, and permeabilized with 0.2% Triton X-100. Immunochemical labeling was performed with a monoclonal antibody to TH (Boehringer Mannheim) and the stain was developed by the avidin-biotin method (Vector Laboratories, Elite Kit) with nickel-intensified 3,3'-diethylaminobenzidine as the chromogen.
The fibroblasts were also examined for the production and release of L-dopa in vitro. Cultured cells were grown 24 hr in DMEM/FCS supplemented with 0.5 mM biopterin, a pterin precursor that fibroblasts can reduce to the required TH cofactor tetrahydropterin (19) . Conditioned media and cells were collected separately, adjusted to 0.1 M perchloric acid (PCA) and 0.05 M EDTA, and centrifuged at 10,000 X g for 15 min at 40C to remove precipitated material. The samples were analyzed for the presence of catecholamines and catecholamine metabolites by injection of PCA extracts onto -a coulometric electrode array, gradient liquid chromatography system (CEAS model 55-0650, ESA, Bedford, MA), equipped with 16 electrochemical sensors and a refrigerated autosampler (20) (21) (22) . The within-run precision for retention time (RT), concentration (C), ratio of lower potential sensor to the dominant sensor (LDR), and ratio of higher potential sensor to the dominant sensor (HDR) for L-dopa were 93.6%, 82.3%, 93.8%, and 90.2%, respectively. The standard gradient method was used as described (23) with two modifications: buffer A, 0.14% SDS in 0.1 M phosphate buffer (pH 3.2); buffer B, 40% methanol in 0.1% phosphate buffer (pH 3.35). Using the CEAS system, response parameters observed for L-dopa in chromatograms of standard solutions (RT = 4.02 ± 0.04, LDR = 0.50 + 0.02, HDR = 0.18 ± 0.03; mean ± SEM; n = 3) and samples (RT = 3.98 + 0.04, LDR = 0.46 + 0.05, HDR = 0.19 ± 0.07; n = 18) were similar. Furthermore, addition of partially purified dopa decarboxylase to standards or samples (370C for 2 hr prior to CEAS analysis) resulted in the elimination of the L-dopa peak and emergence of a peak indicative of dopamine. Finally, chromatograms of experimental samples supplemented with authentic L-dopa displayed a single L-dopa peak. The peak match for parameters (RT, LDR, HDR) in the sample to L-dopa standards, the elimination of the L-dopa peak of dopa decarboxylase, and precise coelution of L-dopa-supplemented samples confers a high degree of confidence in the identification of L-dopa produced by the cultured fibroblasts.
For implantation studies, adult female Sprague-Dawley rats received an injection of the catecholamine neurotoxin 6-hydroxydopamine (12 (25) were included in the study (19 apomorphine tested, 12 amphetamine tested).
Cultured cells were suspended at a density of 80,000 cells Rats with implants of TH-expressing fibroblasts injected into rostral caudate regions (n = 7) showed a significant reduction in drug-induced rotations [t (paired t test) = 2.52; P < 0.05; see Fig. 3 ]. In contrast, there was no significant change in the rotational behavior of rats with TH-expressing cells implanted in caudal areas of the caudate (n = 9). Rotational scores of animals with noninfected fibroblasts injected into either rostral (n = 6) or caudal (n = 5) areas of the caudate were unchanged from pretransplant levels.
Immunohistochemical staining for fibronectin indicated that 27 transplantation into the denervated caudate (Fig. 4) (27) . These results support the idea of functional specificity within subregions of the caudate (28) .
The mechanism through which L-dopa-producing fibroblasts reduce rotational asymmetry in the unilateral lesion model is unclear. However, previous studies using this model have demonstrated an increase in contralateral rotation after systemic administration of L-dopa (29) . Presumably, the effect of L-dopa is mediated through its conversion to dopamine by residual dopa decarboxylase (30) . It has been shown that 20% of decarboxylase activity remains within the caudate even after a 97% reduction in dopamine content resulting from a 6-hydroxydopamine lesion (31) . Even after the unilateral destruction of 95% of nigrostriatal terminals within the caudate, dopamine is increased in both the lesioned and nonlesioned striata after systemic L-dopa administration (29 In the same animal model as used in this study, adrenal medullary cell grafts are able to reduce rotational asymmetry to an extent equivalent to that reported here (32) . Fetal substantia nigra cell grafts, however, have a much greater ability to reverse rotational abnormalities (28 (33) (34) (35) (36) (37) . The ability, demonstrated in this study, to modify cells genetically to produce L-dopa broadens the search for the ideal type of cell for transplantation therapy of Parkinson disease. The 208F rat fibroblasts used in this study were chosen more for technical reasons than for actual clinical applicability. Rat 208F fibroblasts are easily infected in vitro with retroviral vectors and are known to survive for several months after implantation into the rat brain (4). Although we have not observed immunological responses or formations of tumors with these fibroblast grafts, the potential for developing such problems exists. An alternative approach would be to use autografts of primary fibroblasts or glia. Primary cells offer the theoretical advantage of decreased propensity for tumor formation and fewer problems of histoincompatibility. Further work is necessary to determine whether primary cells can be genetically manipulated for use in central nervous system grafting; the long-term survival and functional capabilities of these and other cells could also be examined.
These studies demonstrate that the ability to combine transplantation techniques with gene transfer is potentially a powerful approach to the treatment of human central nervous system dysfunction.
